Literature DB >> 11960639

Regulation of class I MHC expression in skeletal muscle: deleterious effect of aberrant expression on myogenesis.

Grace K Pavlath1.   

Abstract

Aberrant expression of class I major histocompatibility complex (MHC) occurs on myofibers in inflammatory myopathies. The mechanisms responsible for such expression are unknown. Here we show that class I MHC expression is developmentally regulated during muscle regeneration with significant levels only in myoblasts. Injection of gamma-IFN plasmid leads to muscle inflammation, induction of class I MHC in regenerating, but not mature myofibers, and attenuation of regeneration. Gene transfer of class I MHC in vivo and in vitro also attenuates muscle differentiation. Thus, cytokines may contribute to the pathogenesis of inflammatory myopathies by upregulating class I MHC and leading to deleterious effects on muscle repair.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960639     DOI: 10.1016/s0165-5728(02)00026-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  12 in total

Review 1.  Dermatomyositis.

Authors:  M S Krathen; D Fiorentino; V P Werth
Journal:  Curr Dir Autoimmun       Date:  2008

2.  Regeneration of transgenic skeletal muscles with altered timing of expression of the basic helix-loop-helix muscle regulatory factor MRF4.

Authors:  Grace K Pavlath; Janice A Dominov; Kristy M Kegley; Jeffrey Boone Miller
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

3.  Differential genomic responses in old vs. young humans despite similar levels of modest muscle damage after resistance loading.

Authors:  Anna E Thalacker-Mercer; Louis J Dell'Italia; Xiangqin Cui; James M Cross; Marcas M Bamman
Journal:  Physiol Genomics       Date:  2009-11-10       Impact factor: 3.107

4.  Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis.

Authors:  Charles Kwok-chong Li; Paul Knopp; Halima Moncrieffe; Bhanu Singh; Sonia Shah; Kanneboyina Nagaraju; Hemlata Varsani; Bin Gao; Lucy R Wedderburn
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

Review 5.  Advances in the immunopathophysiology of the idiopathic inflammatory myopathies: not as simple as suspected.

Authors:  Gerald J D Hengstman
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

6.  The vitamin D receptor agonist BXL-01-0029 as a potential new pharmacological tool for the treatment of inflammatory myopathies.

Authors:  Luigi Di Luigi; Mariangela Sottili; Cristina Antinozzi; Gabriella Barbara Vannelli; Francesco Romanelli; Valeria Riccieri; Guido Valesini; Andrea Lenzi; Clara Crescioli
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

7.  Pervasive inflammatory activation in patients with deficiency in very-long-chain acyl-coA dehydrogenase (VLCADD).

Authors:  Abbe N Vallejo; Henry J Mroczkowski; Joshua J Michel; Michael Woolford; Harry C Blair; Patricia Griffin; Elizabeth McCracken; Stephanie J Mihalik; Miguel Reyes-Mugica; Jerry Vockley
Journal:  Clin Transl Immunology       Date:  2021-06-27

8.  Skeletal muscle major histocompatibility complex class I and II expression differences in adult and juvenile dermatomyositis.

Authors:  Samuel Katsuyuki Shinjo; Adriana Maluf Elias Sallum; Clovis Artur Silva; Suely Kazue Nagahashi Marie
Journal:  Clinics (Sao Paulo)       Date:  2012-08       Impact factor: 2.365

Review 9.  Developments in the scientific and clinical understanding of inflammatory myopathies.

Authors:  Ingrid E Lundberg; Cecilia Grundtman
Journal:  Arthritis Res Ther       Date:  2008-10-10       Impact factor: 5.156

10.  Skeletal muscle interleukin 15 promotes CD8(+) T-cell function and autoimmune myositis.

Authors:  Po-Lin Huang; Mau-Sheng Hou; Szu-Wen Wang; Chin-Ling Chang; Yae-Huei Liou; Nan-Shih Liao
Journal:  Skelet Muscle       Date:  2015-09-28       Impact factor: 4.912

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.